These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38503525)
1. [Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma]. Ma Y; Xiao XB; Chen XL; Yuan SZ; Lu Y; Zhao SH; Chen JL; Shi GN; Wang YQ; Cheng NN; Feng P; Ding MS; Huang WR Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1016-1021. PubMed ID: 38503525 [No Abstract] [Full Text] [Related]
2. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221 [TBL] [Abstract][Full Text] [Related]
3. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Béné MC; Zweegman S; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Stoppa AM; van de Donk NWCJ; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Krevvata M; Zhang K; de Boer C; Vara S; Kampfenkel T; Vanquickelberghe V; Vermeulen J; Avet-Loiseau H; Sonneveld P Lancet Oncol; 2021 Oct; 22(10):1378-1390. PubMed ID: 34529931 [TBL] [Abstract][Full Text] [Related]
4. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506 [TBL] [Abstract][Full Text] [Related]
5. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419 [TBL] [Abstract][Full Text] [Related]
6. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Voorhees PM; Sborov DW; Laubach J; Kaufman JL; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Bumma N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Dinner S; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG Lancet Haematol; 2023 Oct; 10(10):e825-e837. PubMed ID: 37708911 [TBL] [Abstract][Full Text] [Related]
8. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. Yong K; Wilson W; de Tute RM; Camilleri M; Ramasamy K; Streetly M; Sive J; Bygrave CA; Benjamin R; Chapman M; Chavda SJ; Phillips EH; Del Mar Cuadrado M; Pang G; Jenner R; Dadaga T; Kamora S; Cavenagh J; Clifton-Hadley L; Owen RG; Popat R Lancet Haematol; 2023 Feb; 10(2):e93-e106. PubMed ID: 36529145 [TBL] [Abstract][Full Text] [Related]
9. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. Yimer H; Melear J; Faber E; Bensinger WI; Burke JM; Narang M; Stevens D; Gray KS; Lutska Y; Bobba P; Qi K; Hoehn D; Qi M; Lin TS; Rifkin RM Leuk Lymphoma; 2022 Oct; 63(10):2383-2392. PubMed ID: 35730586 [TBL] [Abstract][Full Text] [Related]
10. [The Efficacy and Safety of Daratumumab-Based Regimen in Treatment of Multiple Myeloma Patients with Renal Impairment]. Yin LL; Shen YL; Min FL; Gu WY; Wang Y; Qi KM; Li ZY; Xu KL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):141-147. PubMed ID: 36765491 [TBL] [Abstract][Full Text] [Related]
11. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ Lancet Oncol; 2021 Nov; 22(11):1582-1596. PubMed ID: 34655533 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma]. Yan S; Jin S; Wang PF; Yan LZ; Shang JJ; Shi XL; Wu XJ; Zhai YY; Yao WQ; Wang J; Yao Y; Fu CC Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):819-825. PubMed ID: 37394852 [No Abstract] [Full Text] [Related]
13. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Yimer H; Melear J; Faber E; Bensinger WI; Burke JM; Narang M; Stevens D; Gunawardena S; Lutska Y; Qi K; Ukropec J; Qi M; Lin TS; Rifkin RM Br J Haematol; 2019 May; 185(3):492-502. PubMed ID: 30828799 [TBL] [Abstract][Full Text] [Related]